A Study to Determine the Safety & Efficacy of ZPL-5212372 in Healthy Subjects and in Subjects With Atopic Dermatitis
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
A Randomised, Adaptive Design, Double-Blind (3rd Party Open), Placebo Controlled, Sequential
Group Study to Determine the Safety,Tolerability, Pharmacokinetics and Efficacy of Twice
Daily Application of a Topical ZPL-5212372 (1.0% w/w) Ointment Administered for up to 2 Weeks
in Adult Healthy Volunteers and Patients with Moderate to Severe Atopic Dermatitis